Update on TACTIC-2 study Triumvira will provide an update on its ongoing TACTIC-2 Phase 1/2 multicenter, open-label trial designed to evaluate the safety, tolerability and efficacy of TAC01-HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback